INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

INOVIO (NASDAQ: INO), a biotechnology company specializing in DNA medicines for HPV-associated diseases, cancer, and infectious diseases, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

The company's President and CEO, Dr. Jacqueline Shea, along with Chief Medical Officer Dr. Michael Sumner, will deliver a presentation on Wednesday, February 12, 2025, from 3:20 to 3:50 PM ET. The management team will also conduct one-on-one meetings with registered investors during the conference.

Interested parties can access the presentation through a webcast available on INOVIO's Investor Relations Events page, with replay access available for 90 days following the presentation.

News Market Reaction – INO

+2.96%

+2.96% Session move

In the trading session that priced this news, INO gained 2.96%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., Jan. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that Dr. Jacqueline Shea, INOVIO's President and CEO, and Dr. Michael Sumner, Chief Medical Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

Oppenheimer 35th Annual Healthcare Life Sciences Conference 
Date: Wednesday, February 12, 2025
Time: 3:20 – 3:50 pm ET
Format: Presentation

During the conference, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors.

A webcast of the presentation will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. A replay of the webcast will be available for 90 days after the date of the presentation.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com 
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505, investor.relations@inovio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-302363750.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

When is INOVIO presenting at the Oppenheimer Healthcare Conference 2025?

INOVIO is scheduled to present at the Oppenheimer Healthcare Conference on Wednesday, February 12, 2025, from 3:20 to 3:50 PM ET.

How can investors watch INOVIO's Oppenheimer Conference presentation?

Investors can watch the presentation via webcast on INOVIO's Investor Relations Events page at ir.inovio.com. A replay will be available for 90 days after the presentation.

Who will be representing INOVIO at the 2025 Oppenheimer Conference?

Dr. Jacqueline Shea, INOVIO's President and CEO, and Dr. Michael Sumner, Chief Medical Officer, will represent the company at the conference.

Will INOVIO management be available for investor meetings at the Oppenheimer Conference?

Yes, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors during the conference.